MIRA INFORM REPORT

Report No. :	345972
Report Date :	23.10.2015

IDENTIFICATION DETAILS

Name :	PHILLIPS PHARMACEUTICALS(ZAMBIA) LIMITED
Registered Office :	Plot No. 7236,Njolwe Road, Light Industrial Area, P. o. Box 36017, Lusaka
Country :	Zambia
Date of Incorporation :	06.12.2004
Com. Reg. No.:	57207
Legal Form :	Limited Corporation
Line of Business :	Subject operate as dealers in pharmaceutical products and medicinal drugs
No. of Employees :	200

RATING & COMMENTS

MIRA’s Rating :

Ba

RATING		STATUS	PROPOSED CREDIT LINE
41-55	Ba	Overall operation is considered normal. Capable to meet normal commitments.	Satisfactory

Status :	Good
Payment Behaviour :	No Complaints
Litigation :	Clear

NOTES:

Any query related to this report can be made on e-mail: infodept@mirainform.com while quoting report number, name and date.

ECGC Country Risk Classification List – March 31, 2015

Country Name	Previous Rating (31.12.2014)	Current Rating (31.03.2015)
Zambia	B1	B1

Risk Category	ECGC Classification
Insignificant	A1
Low	A2
Moderate	B1
High	B2
Very High	C1
Restricted	C2
Off-credit	D

ZAMBIA - ECONOMIC OVERVIEW

Zambia has had one of the world’s fastest growing economies for the past ten years, with real GDP growth averaging roughly 6.7% per annum. Privatization of government-owned copper mines in the 1990s relieved the government from covering mammoth losses generated by the industry and greatly increased copper mining output and profitability, spurring economic growth. Copper output increased steadily from 2004, due to higher copper prices and foreign investment, but weakened in 2014 when Zambia was overtaken by the Democratic Republic of Congo as Africa’s largest copper producer. Zambia's dependency on copper makes it vulnerable to depressed commodity prices, but record high copper prices and a bumper maize crop in 2010 helped Zambia rebound quickly from the world economic slowdown that began in 2008. Despite strong economic growth and its status as a lower middle-income country, widespread and extreme rural poverty and high unemployment levels remain significant problems, made worse by a high birth rate, a relatively high HIV/AIDS burden, and by market-distorting agricultural policies. Economic policy inconsistency and poor budget execution in recent years has hindered the economy and contributed to weakness in the kwacha, which was Africa’s worst performing currency during 2014. Zambia has raised $1.75 billion from international investors by issuing separate sovereign bonds in September 2012 and April 2014, significantly increasing the country’s public debt as a share of GDP. On January 1, 2015, a new mineral royalty tax regime dramatically increased mining taxes, and has led to an economic impasse between the government and the mines. If left intact, the new tax could result in the closure of less profitable mines, the loss of thousands of jobs, and the loss of additional foreign investment.

Source : CIA

Company name
Registered Name:	PHILLIPS PHARMACEUTICALS(ZAMBIA) LIMITED
Requested Name:	PHILLIPS PHARMACEUTICALS(ZAMBIA) LIMITED
Other Names:	None
ADDRESS AND TELECOMMUNICATION
Physical Address:	Plot No. 7236,Njolwe Road, Light Industrial Area
Postal Address:	P. o. Box 36017
	Lusaka,
Country:	Zambia
Phone:	260-211-286037
Fax:	260-211-286037
Email:	None
Website:	None
CREDIT OPINION
Financial Index as of December 2014 shows subject firm with a medium risk of credit. However, bank and credit information obtained reveal a history of prompt payments.
LEGAL
Legal Form:		Limited Corporation
Date Incorporated:		06-Dec-2004
Reg. Number:		57207
Nominal Capital		ZMW. 5,000
Subscribed Capital		ZMW. 5,000
Subscribed Capital is Subscribed in the following form:
		Position		Shares
Mr. Mohmed Ahmed Seedat		MD		1000000
Mr. Sadik Ahmed Seedat		Director		1500000
Mr. Mukesh Sobhagyachand Mehta		Director		1000000
Mr. Shailesh Ramniklal Mehta		Director		1500000
Mr. Balasundaram Krishnamurthy		GM
RELATED COMPANIES
None		Parent company.
None		Subsidiary company.
None		Affiliated company.
Mr. Mohmed Ahmed Seedat Mr. Sadik Ahmed Seedat Mr. Mukesh Sobhagyachand Mehta Mr. Shailesh Ramniklal Mehta		Shareholders of subject firm.
None		Branches of the firm
OPERATIONS
Registered to operate as dealers in pharmaceutical products and medicinal drugs
Imports:		Asia, Middle East
Exports:		None
Trademarks:		None
Terms of sale:		Cash (40%) and 25-90 days (60%), invoices.
Main Customers:		Local agencies, medical stores, outlets etc
Employees:		200 employees.
Vehicles:		Several motor vehicles.
Territory of sales:		Zambia
Location:		Leased premises, 10,000 square feet,
AUDITORS AND INSURANCE
Auditors:		Information not available.
Insurance Brokers:		Information not available.
FINANCE
Currency Reported:		Zambian Kwacha (ZMW.)
Approx. Ex. Rate:		1 US Dollar = 11.96 Zambian Kwacha
Fiscal Year End:		December 31, 2014
Inflation:		According to information given by independent sources, the inflation at December 31st, 2014 was of 13%.
Financial Information not Submitted
Profit and Loss (expressed in ZMW.)
			2014
Sales			10,500,000
BANK
Bank Name:		Stanbic Bank
Branch:		Zambia
Comments:		None
TRADE REFERENCES
Experiences:		Good
NOTARIAL BONDS None
COMMENTS / ADDITIONAL INFORMATION
This information was obtained from outside sources other than the subject company itself and confirmed the above subject.

FOREIGN EXCHANGE RATES

Currency	Unit	Indian Rupees
US Dollar	1	Rs.65.15
UK Pound	1	Rs.100.54
Euro	1	Rs.73.97

INFORMATION DETAILS

Analysis Done by :	DIV
Report Prepared by :	TPT

RATING EXPLANATIONS

RATING		STATUS	PROPOSED CREDIT LINE
>86	Aaa	Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums	Unlimited
71-85	Aa	Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums	Large
56-70	A	Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums	Fairly Large
41-55	Ba	Overall operation is considered normal. Capable to meet normal commitments.	Satisfactory
26-40	B	Capability to overcome financial difficulties seems comparatively below average.	Small
11-25	Ca	Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity	Limited with full security
<10	C	Absolute credit risk exists. Caution needed to be exercised	Credit not recommended
--	NB	New Business	--

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

Financial condition (40%) Ownership background (20%) Payment record (10%)

Credit history (10%) Market trend (10%) Operational size (10%)

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.